ANARI-AI
20.4.2021 14:01:13 CEST | Business Wire | Press release
Anari AI , an AI chip factory in the cloud, today announced it has raised $2 million in seed funding led by Earlybird , with participation from Acequia Capital , Serbian Entrepreneurs , and Eric Ries , author and founder of The Lean Startup . The new funding will be used to continue developing the platform and bring it to market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005700/en/
Anari’s platform makes it possible to design personalized AI chips in the cloud with just one click. With this approach, companies are able to build and deploy AI solutions in weeks instead of 12-18 months, and at a fraction of the cost of traditional hardware development.
“AI continues to be growing in size and complexity, and this rate of growth is outpacing standard CPU and GPU performance gains,” said Roland Manger , co-founder and Partner at Earlybird. “Dedicated designs or flexible architectures are expensive, time-consuming and require hardware skills (in short: take lots of effort). Anari is a game changer in two ways: it removes the trade-off between performance and effort, and it makes AI-problem-specific chip solutions available instantaneously in the cloud. I am excited about this huge potential.”
The platform is built on a unique Python-based programming framework—developed by Anari for chip design—that opens up new possibilities for hardware engineers and turns software engineers into hardware designers. The first configurable AI cloud chip from Anari is Thor X, which delivers 100x more efficient processing of 3D Point Cloud/Graph data structures compared to a high-end GPU.
Anari’s team consists of Ph.D. researchers, machine learning experts, and senior software engineers. The team is led by Jovan Stojanovic (co-founder and CEO), Stefan Sredojevic (co-founder and COO), and Bogdan Vukobratovic (co-founder and Head of R&D). Jovan is the founder of the Wonderland AI community that includes more than 30,000 AI experts and enthusiasts from all over the world. The yearly Wonderland AI Summit gathers C-level speakers and attendees from the world’s leading AI companies like NVIDIA, Airbus, HP, IBM, Mercedes, etc.
“You no longer have to tune your model to the computing infrastructure that’s available and designed for broad and generic use cases,” said Sasha Ostojic , ex-VP at NVIDIA, ex-SVP at Cruise Automation, Advisor at Samsung Electronics and Zoox, and Operating Partner at Playground Global.“ Anari's cloud chip technology is the future of cloud computing.”
Roland Manger and Sasha Ostojic will be joining Anari's Board of Directors. Advisors to the company include Christoph Auer-Welsbach (former Partner at IBM Ventures, Founder of CITY AI, and CEO of Kaizo) and Dejan Markovic (co-founder of Flex Logix and Professor at UCLA).
“With AI model complexity doubling every three and a half months, the current way of building the AI infrastructure is not sustainable,” said Jovan Stojanovic, co-founder and CEO of Anari AI. “We believe that every company deserves to have a personalized chip for their AI in just one click. We’re supporting the rapid progress of AI in ways that haven’t been possible until now. With experienced investors like Earlybird on our side, we’re ready to rebuild the AI hardware industry from scratch.”
About Anari AI
Anari AI is rebuilding the AI hardware industry from scratch by delivering a new way of designing and using AI chips through programming in the cloud. The Anari platform for cloud chips can be used by companies across industries such as gaming, automotive and biotechnology to personalize their AI infrastructure with just one click. The company is based in Serbia and has an office in San Francisco. The global team includes advisors with experience from NVIDIA, CERN, IBM, UC Berkeley, and UCLA.
For more information, visit www.anari.ai .
About Earlybird VC
Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird invests in all growth and development phases of a company. Amongst the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support as well as access to an international network and capital markets.
Earlybird Venture Capital has grown to three autonomous, dedicated and specialized teams, focusing on digital technologies in Eastern and Western Europe as well as health technologies. Among them, the Digital East Fund is focused on early stage ICT investment opportunities in Eastern Europe and Turkey, being the leading tech VC in this region. With EUR 1.5 billion under management, seven IPOs and 30 trade sales, Earlybird is one of the most successful venture capital firms in Europe. Discover more at www.earlybird.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005700/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom